Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5325 - Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: updated Phase II study results including progression-free survival (PFS)

Date

09 Sep 2017

Session

Poster display session

Presenters

Caicun Zhou

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

C. Zhou1, M. Wang2, Y. Cheng3, Y. Chen4, Y. Zhao5, Y. Shi6, M. Ahn7, Y. Chen8, X. Huang9, M. Cantarini10, Y. Wu11

Author affiliations

  • 1 Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 2 Department Of Oncology, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 3 Department Of Oncology, Jilin Province Cancer Hospital, 130012 - Changchun/CN
  • 4 Cancer Centre Of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN
  • 5 Medical Oncology, Henan Cancer Hospital, Zhengzhou/CN
  • 6 Department Of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 86 - Beijing/CN
  • 7 Division Of Hematology/oncology, Department Of Medicine, Samsung Medical Center, Seoul/KR
  • 8 China Development Unit, AstraZeneca, Shanghai/CN
  • 9 Biostatistics And Informatics, AstraZeneca, Cambridge/GB
  • 10 Global Medicines Development, Astrazeneca, SK10 4TG - Macclesfield/GB
  • 11 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, 510080 - Guangzhou/CN
More

Resources

Abstract 5325

Background

Osimertinib is an oral, potent, CNS active, irreversible EGFR-TKI selective for EGFR-TKI sensitising and T790M resistance mutations. AURA17 (NCT02442349) is a Phase II, open-label, single arm study investigating the safety and efficacy of osimertinib in Asia-Pacific pts with T790M-positive advanced NSCLC, who had progressed on prior EGFR-TKI therapy, with or without additional anti-cancer regimens.

Methods

Eligible pts had measureable disease, WHO performance status 0/1 and acceptable organ function; asymptomatic CNS metastases were allowed. T790M-positive status was confirmed by central testing of biopsy samples using the cobas® EGFR Mutation Test. Osimertinib 80 mg was administered orally once daily until disease progression. The primary endpoint was objective response rate (ORR) according to RECIST 1.1 by blinded independent central review. Secondary endpoints included duration of response (DoR), PFS, disease control rate (DCR), overall survival, safety and tolerability.

Results

As of 4 Nov 2016 data cut-off (DCO), 171 pts had received osimertinib (53 [31%] second-line; 118 [69%] ≥third-line), median treatment exposure was 12.3 (range 0.2–14.6) mo. Median age 60 (range 26–82) years; female 68%; Chinese ethnicity 87%; never smokers 78%; EGFR Exon 19 deletion 64%; EGFR L858R mutation 35%; CNS metastases at study entry 37%. Confirmed ORR in pts evaluable for response (n = 166) was 63% (95% confidence interval [CI] 55, 70) and DCR was 89% (95% CI 83, 93). Median DoR was 9.9 mo (95% CI 8.3, not calculable). Median PFS in the full analysis set (n = 171) was 9.7 mo (95% CI 7.0, 11.1); 94 pts (55%) had progression. At DCO, 39 pts had died (23%). All causality adverse events (AEs) of CTCAE Grade ≥3 were reported by 43 (25%) pts. Most common AEs were diarrhoea 35% (Grade ≥3 1%) and rash grouped term 27% (Grade ≥3 0%). There was one reported case of interstitial lung disease and pneumonitis, respectively.

Conclusions

The high ORR of 63% was supported by the durable response assessed by DoR (median 9.9 mo) and PFS (median 9.7 mo). The efficacy data were consistent with global clinical trials of osimertinib. No new safety signals were observed.

Clinical trial identification

NCT02442349

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

C. Zhou: Lecture honorarium: Eli Lily, AZ, Roche, Pfizer, Sanofi, BI, Henrui AB: Roche, BI, AZ. Y. Chen: AstraZeneca employee. X. Huang: I am an employee of AstraZeneca. M. Cantarini: Employee and shareholder of AstraZeneca. Y-L. Wu: Speaker fees from AstraZeneca, Roche, Eli Lilly, Sanofi, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.